Strattera

Strattera Dosage/Direction for Use

atomoxetine

Manufacturer:

Eli Lilly

Distributor:

DKSH
Full Prescribing Info
Dosage/Direction for Use
Initial Treatment: Dosing of Children and Adolescents up to 70 kg body weight: Strattera should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. After 2 to 4 additional weeks, the total daily dose may be increased to a maximum of 1.4 mg/kg in patients who have not achieved an optimal response (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
The maximum recommended total daily dose in children and adolescents is 1.4 mg/kg or 100mg, whichever is less.
Dosing of Children and Adolescents over 70kg body weight and Adults: Strattera should be initiated at a total daily dose of 40mg and increased after a minimum of 3 days to a target total daily dose of approximately 80mg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. After 2 to 4 additional weeks, the dose may be increased to a maximum of 100mg in patients who have not achieved an optimal response (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions). There are no data supporting increased effectiveness at higher doses.
The maximum recommended total daily dose in children and adolescents over 70kg and adults is 100mg.
Interrupted Treatment: If therapy is interrupted for more than 1 week, treatment should be started at the recommended starting dose (see Initial Treatment as previously mentioned).
Maintenance/Extended Treatment: There is no evidence available from controlled trials to indicate how long the patient with ADHD should be treated with Strattera. It is generally agreed, however, that pharmacological treatment of ADHD may be needed for extended periods. Nevertheless, the physician who elects to use Strattera for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.
General Dosing Information: Strattera may be taken with or without food.
The safety of single doses over 120mg and total daily doses above 150mg have not been systematically evaluated.
For those ADHD patients who have end stage renal disease, cautious titration of Strattera to the desired clinical response is recommended (see Pharmacology: Pharmacokinetics under Actions). Atomoxetine may exacerbate hypertension in patients with end stage renal disease.
Strattera may be discontinued without tapering the dose.
Hepatic Impairment Dosage Adjustment: Atomoxetine clearance may be reduced in patients with hepatic impairment. For those ADHD patients who have hepatic impairment, dosage adjustment is recommended as follows: For patients with moderate hepatic impairment (Child-Pugh Class B), initial and target doses should be reduced to 50% of the normal dose. For patients with severe hepatic impairment (Child-Pugh Class C), initial dose and target doses should be reduced to 25% of the normal dose.
Dosing adjustment for use with a strong CYP2D6 inhibitor: In children and adolescents up to 70kg body weight administered strong CYP2D6 inhibitors, e.g. paroxetine, fluoxetine and quinidine, Strattera should be initiated at 0.5 mg/kg/day and only increased to the usual target dose of 1.2 mg/kg/day if symptoms fail to improve after 4 weeks and the initial dose is well tolerated.
In children and adolescents over 70kg body weight and adults administered strong CYP2D6 inhibitors, e.g. paroxetine, fluoxetine and quinidine, Strattera should be initiated at 40 mg/day and only increased to the usual target dose of 80 mg/day if symptoms fail to improve after 4 weeks and the initial dose is well tolerated.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in